Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer
Targeted Oncology · 2026-03 · 21 (2) · 299-307
DOI: 10.1007/s11523-026-01207-2 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Targeted Oncology, online erschienen am 13.03.2026. Verfasst von Nicole L France und 1 weiteren Autor:innen. Beteiligte Einrichtung: Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Lung Neoplasms, Small Cell Lung Carcinoma, Antineoplastic Agents, Immunological. Die Arbeit nennt 35 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. demail@springer.com.
- Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Zitieren
APA
France, N. L., & Syed, Y. Y. (2026). Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer. Targeted Oncology, 21(2), 299-307. https://doi.org/10.1007/s11523-026-01207-2
Vancouver
France NL, Syed YY. Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer. Targeted Oncology. 2026;21(2):299-307. doi:10.1007/s11523-026-01207-2
BibTeX
@article{France2026,
author = {France, Nicole L and Syed, Yahiya Y},
title = {Durvalumab: A Review in Limited-Stage Small Cell Lung Cancer},
journal = {Targeted Oncology},
year = {2026},
volume = {21},
number = {2},
pages = {299--307},
doi = {10.1007/s11523-026-01207-2}
}
EUVIMED